Germany’s New Non-Substitution Drug List No Big Bang For Pharma
This article was originally published in The Pink Sheet Daily
Germany will have its first list of non-substitutable pharmaceuticals since the introduction of discount contracts, but the benefit it offers to original product manufacturers will be severely limited.
You may also be interested in...
This month’s European Notebook scans the horizon for European legislative and regulatory changes affecting the pharmaceutical industry in the next 12 months, including drug price freezes in Germany and the U.K., the heated debate over clinical trial data transparency, the start of the EU unitary patent, and more.
AstraZeneca says that shortages of influenza vaccines in Germany are a direct result of the tendering process there, which has blocked the firm’s Fluenz nasal spray product from being prescribed in several federal states.
Regional firm wins an important tender, but at a discount that is so steep it attacks the process as creating "only losers."